查看購物車
  • Japanese
封面
市場調查報告書
商品編碼
1917312

體外診斷展望（2026）

In Vitro Diagnostics Business Outlook, 2026
出版日期: | 出版商: Kalorama Information | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

體外診斷 (IVD) 產業是現代醫學的基礎性領域，它使臨床醫生能夠檢測疾病、監測健康狀況並做出精準的治療決策。隨著醫療保健的不斷發展，在糖尿病和心血管疾病等慢性病發病率上升以及持續和新出現的傳染病威脅的推動下，IVD 市場正在經歷持續的變化和增長。

"體外診斷展望" 是一份月刊，旨在幫助業內人士在這個快速變化的環境中保持最新動態。該刊每年出版 12 期，每期聚焦在 IVD 產業的不同細分領域，提供及時的洞察、獨家數據和深入的分析。

主要內容

每期月刊提供：

市場數據與預測

詳細的成長率、市場規模和市場佔有率將幫助您發現新的機會。

全面市場展望

體外診斷 (IVD) 產業主要檢測類別和主要參與者的概況。

併購追蹤

關於影響市場的併購、收購、合作和聯盟的最新資訊。

產業與區域趨勢觀察

按地區和細分市場進行的趨勢分析，可協助您制定客製化策略。

深度新聞分析

關於關鍵趨勢和事件的報告，包括您在其他任何地方都找不到的獨家資訊。

2026 年編輯政策

主題每月更新，以反映不斷變化的行業重點。 2026年，訂閱用戶將獲得以下特別內容：

  • 報銷趨勢
  • 品質控制試劑
  • 心臟標記
  • 性傳染感染 (STI) 現場檢測
  • 非呼吸道傳染病
  • 體外診斷市場趨勢分析
  • 呼吸道檢測市場預測（至2027年）
  • 以及更多內容

"體外診斷展望" 每月直接向訂閱用戶提供重點突出、切實可行的信息，幫助決策者預測市場變化、識別增長機會，並自信地駕馭複雜的全球體外診斷行業。

目錄

市場分析：報銷

  • 體外診斷 (IVD) 報銷概覽
  • 展望：報銷

高階主管新聞簡報

  • 簡報
    • Kiffik Biomedical 完成 A 輪融資
    • NeoGenomics 任命 Jack Kenny 為董事會成員
    • Cardio Diagnostics 在印度推出高精準度先天性心臟病 (CHD) 檢測
    • Cyclomics 完成 250 萬歐元融資
    • Truvian 任命新的首席醫療官兼首席策略官
    • Alamar Biosciences 獲得 5,000 萬美元新融資
    • Alamar Biosciences 迎來新的首席科學官
    • Hummingbird Diagnostics 任命新的首席執行官
    • Precede Biosciences 融資 8,350 萬美元

財務亮點

  • 安捷倫宣布 2025 財年營收年增 7%

診斷市場併購及合作協議

  • 併購
  • 合作

產業觀察

  • 產業觀察：新冠疫情/流感最新動態

區域觀察

  • 澳大利亞

博德公司公告

  • 公告
    • Mira Precision Health 在美國推出 ToxNav
    • Beckton Dickinson 獲得 FDA 批准和 CE 認證
    • QuidelOrtho 的 VITROS 免疫診斷產品獲得 FDA 批准
    • FDA 提議對伴隨診斷檢測進行重新分類
    • 國會就 PAMA 法案展開辯論
    • MeMed 加速人工智慧驅動的急診診斷
    • Truvian Health 的九項新增分析獲得批准
簡介目錄
Product Code: 26-014KA

The in vitro diagnostics (IVD) industry is a cornerstone of modern healthcare, empowering clinicians to detect disease, monitor health conditions, and guide treatment decisions with precision. As healthcare continues to evolve-driven by rising rates of chronic conditions such as diabetes and cardiovascular disease, along with ongoing and emerging infectious threats-the IVD market is undergoing constant change and growth.

In Vitro Diagnostics Business Outlook is a monthly intelligence publication designed to help industry professionals stay current in this fast-moving environment. Delivered in 12 issues annually, each issue focuses on a different segment of the IVD industry, providing timely insights, exclusive data, and in-depth analysis.

Featured Content

Each monthly issue provides:

Market Data and Forecasts

Detailed growth rates, market size, and market share to help identify emerging opportunities.

Comprehensive Market View

Coverage of key test categories and profiles of active companies across the IVD landscape.

M&A Activity Tracking

Updates on mergers, acquisitions, partnerships, and collaborations shaping the market.

Industry & Region Watch

Analysis of regional and segment-specific trends to support tailored strategic planning.

In-Depth News Analysis

Reporting on significant developments and events, including exclusive information not readily available elsewhere.

2026 Editorial Focus

Topics vary month to month, reflecting evolving industry priorities. In 2026, subscribers can expect issues dedicated to:

  • Reimbursement trends
  • Quality control reagents
  • Cardiac markers
  • STI point-of-care testing
  • Non-respiratory infectious diseases
  • An overall IVD market trend analysis
  • A forward-looking forecast of the respiratory testing market through 2027
  • And more!

By delivering focused, actionable intelligence directly to subscribers' each month, In Vitro Diagnostics Business Outlook helps decision-makers anticipate market shifts, identify growth opportunities, and navigate the complexities of the global IVD industry with confidence.

Table of Contents

Market Analysis: Reimbursement

  • Overview of IVD Reimbursement
  • Outlook: Reimbursement
    • Figure: CMS Average Reimbursement Trend: 40+ High-Frequency Clinical Laboratory Test Codes
    • Table: CMS Reimbursement Limit by Clinical Laboratory Test Code, 2010, 2015, 2020, and 2025
    • Table: Select Companies/Products Expected 2026 Reimbursement Impact
    • Table: Summary of Key Reimbursement Drivers

Executive News Briefing

  • Briefings
    • Kiffik Biomedical Closes Series A Financing
    • NeoGenomics Appoints Jack Kenny to Board of Directors
    • Cardio Diagnostics Launches Precision CHD Test in India
    • Cyclomics Closes Euro-2.5 Million Investment Round
    • Truvian Appoints New Chief Medical and Strategy Officer
    • Alamar Biosciences Closes $50 Million in New Capital
    • Alamar Biosciences Welcomes New CSO
    • Hummingbird Diagnostics Appoints New CEO
    • Precede Biosciences Nabs $83.5 Million in Total Financing

Financial Highlights

  • Agilent Full Year Fiscal 2025 Sales up 7% in Business YOY
    • Figure: Agilent Sales by Business, FY 2024 and 2025 ($)
    • Figure: Agilent Sales by Business, FY 2025 Quarterly Performance ($)
    • Table: Agilent Revenue Mix, by Type, FY 2025 (%)
    • Figure: Agilent FY 2025 Regional Sales Breakdown Distribution (%)

Diagnostic Market Mergers, Acquisitions, and Partnership Deals

  • Mergers and Acquisitions
    • Table: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals
  • Partnerships and Collaborations

Industry Watch

  • Industry Watch COVID-19/Flu Update

Region Watch

  • Australia
    • Figure: Australia Exports, Distribution by Industry Segment, 2023 ($ billion)
    • Figure: Australia IVD Market Sales Trend, 2020-2025 ($ million)

Broad-based Company Announcements

  • Announcements
    • Mira Precision Health Launches ToxNav in U.S.
    • Beckton Dickinson Receives FDA Clearance and CE Marking
    • QuidelOrtho Captures FDA Clearance or VITROS Immunodiagnostic
    • FDA Proposes Reclassification of Companion Diagnostic Assays
    • Congress Discusses PAMA
    • MeMed Accelerates AI-enabled Acute-Care Diagnostics
    • Truvian Health Snags Clearance for Nine Additional Analytes